ストックスクリーナーアプリを入手
4.83
0.82%
-0.04
プレマーケット:
4.86
0.03
+0.62%
前日終値:
$4.87
開ける：
$4.87
24時間の取引高:
1.77M
Relative Volume:
0.44
時価総額：
$501.75M
収益：
-
当期純損益:
$-165.67M
株価収益率:
-2.188
EPS:
-2.2075
ネットキャッシュフロー:
$-113.29M
1週間 パフォーマンス:
-5.11%
1か月 パフォーマンス:
+5.11%
6か月 パフォーマンス:
+13.92%
1年 パフォーマンス:
+156.91%
1日の値動き範囲:
$4.775
$5.00
1週間の範囲:
$4.69
$5.18
52週間の値動き範囲:
$1.73
$6.42
Larimar Therapeutics Inc Stock (LRMR) Company Profile
名前
Larimar Therapeutics Inc
セクター
電話
844-511-9056
住所
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
4.83 | 505.91M | 0 | -165.67M | -113.29M | -2.2075 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-29 | 開始されました | Truist | Buy |
| 2024-10-16 | 開始されました | Oppenheimer | Outperform |
| 2024-10-03 | 開始されました | Wedbush | Outperform |
| 2024-10-02 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-04 | 開始されました | Robert W. Baird | Outperform |
| 2024-04-03 | 開始されました | Leerink Partners | Outperform |
| 2023-11-17 | アップグレード | Citigroup | Neutral → Buy |
| 2022-10-19 | 開始されました | Guggenheim | Buy |
| 2022-02-15 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-02-10 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-02-01 | 開始されました | William Blair | Outperform |
すべてを表示
Larimar Therapeutics Inc (LRMR) 最新ニュース
LRMR stock on the move: What sparked the 55% jump in the past month? - MSN
FDA grants breakthrough status to Larimar’s nomlabofusp - MSN
Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development - MSN
Larimar Therapeutics (NASDAQ: LRMR) asks shareholders to double authorized shares to 215M - Stock Titan
LRMR Forecast, Price Target & Analyst Ratings | LARIMAR THERAPEUTICS INC (NASDAQ:LRMR) - ChartMill
Analysts Set Larimar Therapeutics Price Target at $16.50 - National Today
Investment Review: Is Larimar Therapeutics Inc currently under institutional pressure2026 Breakouts & Breakdowns & Stepwise Swing Trade Plans - baoquankhu1.vn
Pullback Watch: Is Larimar Therapeutics Inc forming a double bottom2026 Earnings Surprises & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Pharma News: Is Larimar Therapeutics Inc impacted by rising ratesWeekly Stock Summary & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Larimar surges on FDA breakthrough status for lead asset - MSN
LRMR Technical Analysis & Stock Price Forecast - Intellectia AI
LRMR PE Ratio & Valuation, Is LRMR Overvalued - Intellectia AI
Biotech Larimar heads to Miami for back-to-back investor meetings in March - Stock Titan
Q1 Earnings Estimate for LRMR Issued By Lifesci Capital - MarketBeat
LRMR SEC FilingsLarimar Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Larimar reports results, advances Nomlabofusp toward FDA filing - MSN
Earnings Recap: Does Larimar Therapeutics Inc have consistent dividend growthMarket Growth Review & High Conviction Buy Zone Alerts - baoquankhu1.vn
Buyback Watch: Is Larimar Therapeutics Incs growth already priced in2026 Weekly Recap & Daily Entry Point Trade Alerts - baoquankhu1.vn
Trend Report: Is Larimar Therapeutics Inc impacted by rising ratesProfit Target & Weekly Top Gainers Trade List - baoquankhu1.vn
Wedbush raises its price target on Larimar Therapeutics (LRMR) to $13 - MSN
Profit Recap: Will Larimar Therapeutics Inc stock hit new highs in YEAR2026 Earnings & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Wedbush Raises its Price Target on Larimar Therapeutics (LRMR) to $13 - Insider Monkey
Larimar Reports Results, Advances Nomlabofusp Toward FDA Filing - MyChesCo
Larimar Therapeutics (NASDAQ:LRMR) Stock Rating Upgraded by Truist Financial - MarketBeat
RSI Check: Will Larimar Therapeutics Inc benefit from geopolitical trendsWeekly Trading Summary & Consistent Growth Stock Picks - baoquankhu1.vn
Larimar heads to JPMorgan as rare disease program draws investor attention - MSN
Larimar Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Larimar Therapeutics (LRMR) Expected to Announce Earnings on Monday - MarketBeat
Institution Moves: Is Larimar Therapeutics Inc impacted by rising ratesTrade Exit Report & Low Risk Entry Point Tips - baoquankhu1.vn
Larimar Therapeutics (NASDAQ:LRMR) Stock Price Up 8.2% After Analyst Upgrade - MarketBeat
Wedbush Increases Larimar Therapeutics (NASDAQ:LRMR) Price Target to $13.00 - MarketBeat
LRMR Stock: Wedbush Raises Price Target to $13, Maintains Outper - GuruFocus
Larimar Therapeutics (LRMR) Q4 EPS Misses Estimates - GuruFocus
Larimar Therapeutics stock rating reiterated by William Blair - Investing.com Canada
Nomlabofusp push at Larimar Therapeutics (NASDAQ: LRMR) targets 2026 BLA - Stock Titan
Larimar Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Larimar Therapeutics reports Q4 EPS (73c), consensus (55c) - TipRanks
Larimar (LRMR) Poised for Milestone Achievements and Financial S - gurufocus.com
Larimar Therapeutics, Inc. has established a clear regulatory approval and commercialization timeline for its core candidate product. - Bitget
Larimar: Q4 Earnings Snapshot - 10TV
Larimar Therapeutics Receives Breakthrough Therapy Designation for Nomlabofusp in Friedreich's Ataxia, Plans BLA Submission for June 2026 - Quiver Quantitative
LRMR: Nomlabofusp advances toward BLA submission with strong cash position and FDA alignment - TradingView
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Larimar Therapeutics Q4 net loss widens on higher R&D costs - TradingView
Larimar (NASDAQ: LRMR) secures FDA Breakthrough status and funds runway to 2027 - Stock Titan
Larimar Therapeutics Inc (LRMR) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):